TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8041536

Group type: EXPERIMENTAL
Intervention: Negative modified biophysical profile
Number of subjects: 5444

Group type: COMPARATOR
Intervention: Negative contraction stress test (CST)
Number of subjects: 5444
Study: 2925967

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weight Lifting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed Treatment (Control)
Number of subjects: 40
Study: 4103276

Group type: EXPERIMENTAL
Intervention: 1,000 mug of anti-D gammaglobulin given intramuscularly
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 349
Study: 31422715

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (pneumatic circulation with compression garments)
Number of subjects: 48
Study: 28867310

Group type: EXPERIMENTAL
Intervention: High baseline negative affect (NA)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Low baseline negative affect (NA)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: High baseline positive affect (PA)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Low baseline positive affect (PA)
Number of subjects: 230
Study: 26590506

Group type: EXPERIMENTAL
Intervention: 9-hour duty day with multiple take-offs and landings
Number of subjects: 24

Group type: COMPARATOR
Intervention: 9-hour duty day with a single take-off and landing
Number of subjects: 24
Study: 25188489

Group type: EXPERIMENTAL
Intervention: Simulation with black standardized patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Simulation with white standardized patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Privately insured black patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medicaid-insured white patients
Number of subjects: 31
Study: 21974992

Group type: EXPERIMENTAL
Intervention: Vaginal repair with mesh
Number of subjects: 65

Group type: COMPARATOR
Intervention: Vaginal repair without mesh
Number of subjects: 65
Study: 19095871

Group type: EXPERIMENTAL
Intervention: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.4% ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 50
Study: 17545351

Group type: EXPERIMENTAL
Intervention: Computerised decision support tool
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard gamble values elicitation exercise
Number of subjects: 30
Study: 14670395

Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 11897179

Group type: EXPERIMENTAL
Intervention: Enrolled African American smokers who returned for randomization
Number of subjects: 287

Group type: COMPARATOR
Intervention: Enrolled African American smokers who did not return for randomization
Number of subjects: 287
Study: 10442506

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily (doubled to 7.1 mg daily if diastolic blood pressure > 90 mmHg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enalapril 20 mg daily (doubled dosage if diastolic blood pressure > 90 mmHg)
Number of subjects: 24
Study: 7503838

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Ibuprofen (with at least 70% compliance)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 2217684

Group type: EXPERIMENTAL
Intervention: Amoxycillin (3 g) twice daily for 32 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo twice daily for 32 weeks
Number of subjects: 38
Study: 623256

Group type: EXPERIMENTAL
Intervention: Underwater weighing
Number of subjects: 67

Group type: COMPARATOR
Intervention: Water displacement
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Comparison of both techniques
Number of subjects: 67
Study: 30621837

Group type: EXPERIMENTAL
Intervention: Unguided Internet CBT-I
Number of subjects: 95
Study: 27939495

Group type: EXPERIMENTAL
Intervention: Tachyarrhythmias (20% of subjects)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Atrioventricular block (4% of subjects)
Number of subjects: 544
Study: 26316351

Group type: EXPERIMENTAL
Intervention: 10 Hz cerebellar rTMS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Optimal train length of 250 pulses of 10 Hz cerebellar rTMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham cerebellar rTMS
Number of subjects: 17
Study: 23508339

Group type: EXPERIMENTAL
Intervention: Fixed-order practice
Number of subjects: 25

Group type: COMPARATOR
Intervention: Random-order practice
Number of subjects: 25
Study: 21513688

Group type: EXPERIMENTAL
Intervention: Very-low-dose naltrexone (VLNTX) 0.125 or 0.250 mg/day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 19141364

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation stress coping program (90-min sessions for eight weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study: 17679044

Group type: EXPERIMENTAL
Intervention: A/B antihypertensive agents
Number of subjects: 175

Group type: COMPARATOR
Intervention: C/D antihypertensive agents
Number of subjects: 175
Study: 15385805

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (0.05, 0.5, 1.0, or 2.0 mg/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ISIS 2302
Number of subjects: 56
Study: 11351767

Group type: EXPERIMENTAL
Intervention: Combined DTP-HBV vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Separate DTP and HBV vaccines
Number of subjects: 120
Study: 9562774

Group type: EXPERIMENTAL
Intervention: New diagnostic instruments such as electrocardiography and new research designs such as randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of a questionnaire on the health of the elderly and introduction of the concept of activities of daily living
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methodological problems encountered by researchers
Number of subjects: 0
Study: 9829346

Group type: EXPERIMENTAL
Intervention: History of diabetes (self-reported)
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Elevated fasting plasma glucose (FPG)
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (FPG)
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Diabetes history
Number of subjects: 3654

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 3654
Study: 1750041

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy performed by approved surgeons
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy performed on asymptomatic patients
Number of subjects: 164
Study: 6315038

Group type: EXPERIMENTAL
Intervention: DAMME (0.25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 6
Study: 30877186

Group type: EXPERIMENTAL
Intervention: 17.5 mg PF‐06372865
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 52.5 mg PF‐06372865
Number of subjects: 7

Group type: COMPARATOR
Intervention: 2 mg lorazepam (active control)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 28064115

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo followed by Duloxetine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine or Bupropion (for duloxetine non-responders)
Number of subjects: 50
Study: 27055214

Group type: EXPERIMENTAL
Intervention: Conjunctival autograft (CAG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 33
Study: 24517906

Group type: EXPERIMENTAL
Intervention: BoNTA (5 U)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (0.2 mL)
Number of subjects: 0
Study: 22237063

Group type: EXPERIMENTAL
Intervention: Leptin (replacement doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (twice-daily injections)
Number of subjects: 10
Study: 21182601

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mephentermine
Number of subjects: 60
Study: 18222414

Group type: EXPERIMENTAL
Intervention: Dry surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wet surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycerol-contaminated surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low load (0 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium load (295 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High load (568 kg)
Number of subjects: 0
Study: 15733152

Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 13

Group type: COMPARATOR
Intervention: Modified Widman flap
Number of subjects: 13
Study: 12527321

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections (0.1 ml of 0.9%, 2%, 4%, and 6% and 0.2 ml of 2% and 4%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 4% saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (isotonic saline injections)
Number of subjects: 10
Study: 10577682

Group type: EXPERIMENTAL
Intervention: Alpha‐Cradle mattress (AM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orfit cast (OC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No immobilisation device (NI)
Number of subjects: 30
Study: 9410673

Group type: EXPERIMENTAL
Intervention: Extended drainage operation according to Frey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple drainage procedures (longitudinal pancreaticojejunostomy)
Number of subjects: 0
Study: 8195851

Group type: EXPERIMENTAL
Intervention: Brodimoprim 200 mg tablets (2 tablets on the first day, 1 tablet on following days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Josamycin 500 mg tablets (3 tablets/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 80

Group type: COMPARATOR
Intervention: Brodimoprim and Josamycin
Number of subjects: 80
Study: 3515951

Group type: EXPERIMENTAL
Intervention: Single 2 gm dose of cefotetan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Multidose cefoxitin (2 gm every 4 hours for three doses)
Number of subjects: 70
Study: 31903435

Group type: EXPERIMENTAL
Intervention: Active VNS (0.8 mA) paired with upper limb rehabilitation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control VNS (0.0 mA) paired with upper limb rehabilitation
Number of subjects: 120
Study: 29335039

Group type: EXPERIMENTAL
Intervention: Whole eggs (EGG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Egg whites (WHITE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose (GLU)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Egg yolks (YOLK)
Number of subjects: 20
Study: 26781404

Group type: EXPERIMENTAL
Intervention: Volume-targeted ventilation (VTV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 52
Study: 23486918

Group type: EXPERIMENTAL
Intervention: dual-tDCS
Number of subjects: 19

Group type: COMPARATOR
Intervention: sham
Number of subjects: 19
Study: 22103390

Group type: COMPARATOR
Intervention: Palpation-guided arthrocentesis with a conventional 20-mL syringe
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: US-guided arthrocentesis with a 25-mL reciprocating procedure device (RPD) mechanical aspirating syringe
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: US-guided arthrocentesis with a 60-mL automatic aspirating syringe
Number of subjects: 64
Study: 19067474

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 400 microg administered via a dry powder inhaler once daily in the evening (MF‐DPI 400 microg qd pm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered between 6 pm and 8 pm for 14 days
Number of subjects: 20
Study: 17469029

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy (ESWL)
Number of subjects: 284
Study: 16045025

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine (3.0 mL, 15 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (3.0 mL, 15 mg)
Number of subjects: 160
Study: 11896484

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs (Selective Serotonin Reuptake Inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 0
Study: 8123997

Group type: EXPERIMENTAL
Intervention: bFGF (bovine fibroblast growth factor) administered intramuscularly at dosages of 0.4 or 0.28 microgram kg-1, once or twice a month, over 7-12 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: bFGF (bovine fibroblast growth factor) administered intramuscularly
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 95
Study: 2442538

Group type: EXPERIMENTAL
Intervention: Intravenous enalaprilat (ET) 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral enalapril (E) 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous enalapril (E) 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral lisinopril (LI) 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous lisinopril (LI) 5 mg
Number of subjects: 24
Study: 29758176

Group type: EXPERIMENTAL
Intervention: Self-administered DMPA-SC
Number of subjects: 731

Group type: COMPARATOR
Intervention: Provider-administered DMPA-SC
Number of subjects: 731
Study: 28241271

Group type: EXPERIMENTAL
Intervention: Standard pillbox
Number of subjects: 53480

Group type: EXPERIMENTAL
Intervention: Digital timer cap
Number of subjects: 53480

Group type: EXPERIMENTAL
Intervention: Pill bottle strip with toggles
Number of subjects: 53480

Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 53480
Study: 26301654

Group type: EXPERIMENTAL
Intervention: Invasive strategy (IS)
Number of subjects: 3670
Study: 24649788

Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE) analgesia
Number of subjects: 112

Group type: COMPARATOR
Intervention: Continuous labor epidural (CLE) analgesia
Number of subjects: 112
Study: 20804848

Group type: EXPERIMENTAL
Intervention: Caloric orangeade (10% sucrose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-caloric orangeade (non-caloric sweeteners)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Small sips (5 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Large sips (20 mL)
Number of subjects: 10
Study: 18577289

Group type: EXPERIMENTAL
Intervention: Levodopa administration (on condition)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No drug administration (off condition)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 16842440

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a (40 kDa) plus ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 14604194

Group type: COMPARATOR
Intervention: High protein diet (1.4 g natural protein/kg target weight/day and 35 kcal/kg target weight/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calcium caseinate (0.7 g calcium caseinate plus 0.7 g natural protein diet/kg target weight/day and 35 kcal/kg target weight/day)
Number of subjects: 100
Study: 10790464

Group type: EXPERIMENTAL
Intervention: rHuEPO (1250 units/kg/week; IV)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (late group)
Number of subjects: 114
Study: 9148240

Group type: EXPERIMENTAL
Intervention: Amyloid beta protein (A beta), A beta 40, A beta 42, and transthyretin (TTR) immunohistochemical localization
Number of subjects: 0
Study: 8450109

Group type: EXPERIMENTAL
Intervention: Behavioral marital therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Insight-oriented marital therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Termination measures of negative marital affect and poor communication skills
Number of subjects: 55
Study: 3300270

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (0.05%) mouthrinse, nightly rinse
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weekly topical APF treatment (1.2% fluoride)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weekly topical APF treatment (1.2% fluoride) and sodium fluoride (0.05%) mouthrinse, nightly rinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (dentifrice only)
Number of subjects: 20
Study: 31183796

Group type: EXPERIMENTAL
Intervention: Cold jumbo forceps polypectomy (JFP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 151
Study: 29713800

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27658756

Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) for smoking abstinence
Number of subjects: 340

Group type: COMPARATOR
Intervention: Noncontingent vouchers (NV)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: NRT (Nicotine Replacement Therapy)
Number of subjects: 340
Study: 26351027

Group type: EXPERIMENTAL
Intervention: Continuation of antihypertensive treatment (n=47)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Discontinuation of antihypertensive treatment (n=55)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Overall BP parameters (systolic, diastolic, mean arterial pressure, pulse pressure, BP changes on standing)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Subgroups with small vessel-related cerebral pathologies, lower cognition, or diabetes mellitus
Number of subjects: 203
Study: 24289740

Group type: EXPERIMENTAL
Intervention: Online psycho-educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief generic information about depression (control)
Number of subjects: 0
Study: 21472373

Group type: COMPARATOR
Intervention: Melphalan plus prednisone (MP)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Thalidomide with melphalan/prednisone (MPT)
Number of subjects: 284
Study: 18538774

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 5238

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5238
Study: 17854523

Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration (group B)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Coasting (group A)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study: 15129927

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg calcium citrate/400 I.U. Vitamin D)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11304901

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg bid for 7 days, then 75 mg bid until Day 28)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily for 28 days)
Number of subjects: 28
Study: 9345339

Group type: EXPERIMENTAL
Intervention: TNF 80 micrograms/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TNF 40 micrograms/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of TNF, IL-2, and IFN-alpha
Number of subjects: 18
Study: 8093745

Group type: EXPERIMENTAL
Intervention: Measurement of metabolic acidosis markers (base deficit in blood and extracellular fluid, bicarbonate concentration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood base deficit of -4.65 or less
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Extracellular-fluid base deficit of -6.13 or less
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Routine blood-gas measurements
Number of subjects: 20
Study: 3481160

Group type: EXPERIMENTAL
Intervention: Combination of 1.0 mM CuSO4 and 2.0 mM hexetidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: 1.0 mM CuSO4
Number of subjects: 7

Group type: COMPARATOR
Intervention: 2.0 mM hexetidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: H2O
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hexetidine
Number of subjects: 7
Study: 29957750

Group type: EXPERIMENTAL
Intervention: Fluticort plus®
Number of subjects: 80

Group type: COMPARATOR
Intervention: Seretide®
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluticort plus® and Seretide®
Number of subjects: 80
Study: 27742728

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study: 26537500

Group type: EXPERIMENTAL
Intervention: Supervised pharmacy student-led medication review
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 133
Study: 24097128

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg three times daily
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid 500 mg/125 mg three times daily
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 20381077

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 40), continuous infusion at a rate of 0.73 mg/min for 96 hours (total dose 4200 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40), no prophylaxis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 80
Study: 17716953

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention combining behavioral counseling and nicotine replacement (open-label)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight gain prevention lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure control lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual lifestyle intervention
Number of subjects: 0
Study: 17160761

Group type: EXPERIMENTAL
Intervention: Plexiglas hysterosalpingographic vacuum cup
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard two-way catheter
Number of subjects: 226